Abstract
Dabigatran (Pradaxa) is a member of the relatively new class of antithrombotic drugs known as direct thrombin inhibitors (DTIs). It may supplant warfarin (Coumadin) in a number of applications as it may produce a more predictable, potent, and immediate anticoagulant effect, with fewer significant side effects and interactions, and requires less monitoring.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 426-428 |
| Number of pages | 3 |
| Journal | American Journal of Neuroradiology |
| Volume | 33 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 2012 |
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
- Clinical Neurology
Fingerprint
Dive into the research topics of 'Dabigatran (Pradaxa)'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS